Advertisement
UK markets close in 6 hours 19 minutes
  • FTSE 100

    7,874.99
    +27.00 (+0.34%)
     
  • FTSE 250

    19,418.84
    +78.70 (+0.41%)
     
  • AIM

    744.47
    +1.35 (+0.18%)
     
  • GBP/EUR

    1.1679
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.2474
    +0.0018 (+0.14%)
     
  • Bitcoin GBP

    49,286.29
    -1,592.70 (-3.13%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     
  • DOW

    37,753.31
    -45.66 (-0.12%)
     
  • CRUDE OIL

    82.08
    -0.61 (-0.74%)
     
  • GOLD FUTURES

    2,394.80
    +6.40 (+0.27%)
     
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     
  • DAX

    17,779.18
    +9.16 (+0.05%)
     
  • CAC 40

    8,021.90
    +40.39 (+0.51%)
     

Taking Stock of Radius Health’s Financial Performance

Taking Stock of Radius Health’s Financial Performance

Of this revenue, $3.4 million came from product revenue, which comprises Tymlos sales and licensing revenue. For 2017 and 2018, Radius Health is expected to post revenue of $23 million and $97.7 million, respectively. Array Biopharma (ARRY) is expected to report revenue of $108 million in 2018.